CN105250376A - Composition having gastric mucosa protecting effect and application thereof - Google Patents
Composition having gastric mucosa protecting effect and application thereof Download PDFInfo
- Publication number
- CN105250376A CN105250376A CN201510860124.1A CN201510860124A CN105250376A CN 105250376 A CN105250376 A CN 105250376A CN 201510860124 A CN201510860124 A CN 201510860124A CN 105250376 A CN105250376 A CN 105250376A
- Authority
- CN
- China
- Prior art keywords
- gastric mucosa
- aspirin
- composition
- radix salviae
- salviae miltiorrhizae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a composition having the gastric mucosa protecting effect and application thereof. The composition is an oral preparation or injection prepared from a salvia miltiorrhiza and safflower composition. The salvia miltiorrhiza and safflower composition with optimum proportion is screened out based on the compatibility theory of traditional Chinese medicine prescriptions and a great deal of experimental research. The composition has the remarkable gastric mucosa protecting effect, especially has the good protecting and recovering effects on gastric mucosa injury caused by aspirin and can alleviate the gastrointestinal adverse effect caused by the aspirin. The composition can effectively prevent and treat gastric mucosa injury and has important application prospect.
Description
Technical field
The present invention relates to a kind of medicine, a kind of compositions and the application of said composition in control mucosal lesion with the protective effects on gastric mucosa of specific design.
Background technology
Mucosal lesion is the main pathological process causing gastric ulcer and acute and chronic gastritis, because between gastric mucosa defense factor and attack factor, disequilibrium causes.Gastric mucosa defense factor comprises mucus-bicarbonate barrier, gastric epithelial cells barrier, Gastric Mucosa Blood Flow amount etc.; The attack factor of mucosal lesion is caused to comprise smoking, gastric acid, pepsin, helicobacter pylori, NSAID (non-steroidal anti-inflammatory drug), stress and psychological factor etc.Currently reduce mucosal lesion mainly through strengthening defense factor or reducing attack factor these two approach, but mucosal lesion still affects the life of people.Such as, aspirin is one of the most widely used medicine in the world, its modal untoward reaction is exactly mucosal lesion, many application Aspirin Enteric-coated Tabletss evade this risk clinically now, but still have a large amount of Pharmacoepidemiological studies to show, the upper gastrointestinal hemorrhage risk that Aspirin Enteric-coated Tablets causes is suitable with non-coated aspirin, and this just means that Aspirin Enteric-coated Tablets can not reduce the risk of upper gastrointestinal hemorrhage.But, in view of aspirin ease pain significantly, antiinflammatory and antiplatelet effects, aspirin application is clinically still very extensive.Therefore, aspirin is a benefit and risk and the medicine deposited.Such as, in 1000 patients of taking small dose of aspirin, there is 12-40 patient can benefit from the antiplatelet effects of aspirin, simultaneously also by there being 2-4 patient can be subjected to the gastrointestinal side effect of aspirin, occurring upper gastrointestinal hemorrhage symptom.
Therefore, necessary curative effect of developing on the basis of prior art is reliable, and untoward reaction is low, effectively can prevent and treat the medicine of mucosal lesion.
Summary of the invention
Goal of the invention: technical problem to be solved by this invention overcomes the deficiencies in the prior art, provide a kind of curative effect reliable, untoward reaction is low, effectively can prevent and treat the medicine of mucosal lesion.
Technical scheme: in order to realize above object, the technical scheme that the present invention takes is:
Have a compositions for the protective effects on gastric mucosa, it is made up of the raw material of following parts by weight: Radix Salviae Miltiorrhizae 1 ~ 10 part, 2 ~ 6 parts, Flos Carthami.
Preferably, the above-described compositions with the protective effects on gastric mucosa, is characterized in that, it is made up of the raw material of following parts by weight: Radix Salviae Miltiorrhizae 8 ~ 10 parts, 2 ~ 4 parts, Flos Carthami.
As more preferably scheme, the above-described compositions with the protective effects on gastric mucosa, is characterized in that, it is made up of the raw material of following parts by weight: Radix Salviae Miltiorrhizae 3 parts, 1 part, Flos Carthami.
Have a medicine for the protective effects on gastric mucosa, it is the oral formulations or ejection preparation be made up of the extract of Radix Salviae Miltiorrhizae 3 parts of Flos Carthami 1 part and pharmaceutically acceptable carrier.
The application of compositions in preparation control mucosal lesion medicine with the protective effects on gastric mucosa provided by the invention.
Application in the mucosal lesion that the compositions with the protective effects on gastric mucosa provided by the invention causes at control aspirin.
Application in the mucosal lesion that the medicine with the protective effects on gastric mucosa of the present invention causes at control aspirin.
During as compositions provided by the invention made Radix Salviae Miltiorrhizae Flos Carthami injection, get Radix Salviae Miltiorrhizae 3 parts and 1 part, Flos Carthami, decoct with water twice, each 60min, filter, filtrate merges the clear paste of simmer down to relative density 1.20-1.30 (65 DEG C), add ethanol to alcohol content 75-80%, cold preservation, get supernatant, reclaim ethanol and the clear paste of simmer down to relative density 1.20-1.30, add ethanol to alcohol content 80-85%, cold preservation, get supernatant, add the active carbon being about inventory 1%, stir 30min, leave standstill, filter, filtrate recycling ethanol is extremely without alcohol taste, add water to amount of preparation, stir evenly, heated and boiled 40-50min, cold preservation, filter, filtrate is concentrated into 1/3 of amount of preparation, cold preservation, filter, filtrate by NaOH solution adjust ph to 6.5-7.5, heated and boiled 40-50min, add the active carbon being about amount of liquid medicine 0.5%, stir evenly, fluid temperature is down to 50-60 DEG C, leave standstill, filter, filtrate is after ultrafiltration, add the active carbon being about amount of liquid medicine 0.5%, boil, filter, filtrate injects water to 1000mL, adjust ph is to 6.5-7.5, filter, embedding, sterilizing.
Beneficial effect: the oral and ejection preparation that Radix Salviae Miltiorrhizae Flos Carthami compositions provided by the invention is made obviously can alleviate the damage of aspirin to gastric mucosa, has good protective effect to gastric mucosa.Radix Salviae Miltiorrhizae Flos Carthami compositions and aspirin combination medication, can not only work in coordination with effect of aspirin control thrombosis, can also reduce aspirin caused gastrointestinal side effect, have important application prospect.
Detailed description of the invention
Below in conjunction with specific embodiment, illustrate the present invention further, these embodiments should be understood only be not used in for illustration of the present invention and limit the scope of the invention, after having read the present invention, the amendment of those skilled in the art to the various equivalent form of value of the present invention has all fallen within the application's claims limited range.
The gastric mucosal protection experiment of the Radix Salviae Miltiorrhizae Flos Carthami compositions of embodiment 1 different ratio and dosage form
1. experimental technique
1.1 experiment material
Radix Salviae Miltiorrhizae Flos Carthami composite injection: Radix Salviae Miltiorrhizae Flos Carthami (C1,1 part, the Radix Salviae Miltiorrhizae 3 parts-Flos Carthami of getting Different Weight ratio, C2,1 part, Radix Salviae Miltiorrhizae 1 part-Flos Carthami, C3, 3 parts, Radix Salviae Miltiorrhizae 1 part-Flos Carthami), decoct with water twice, each 60min, filter, filtrate merges the clear paste of simmer down to relative density 1.20-1.30 (65 DEG C), add ethanol to alcohol content 75-80%, cold preservation, get supernatant, reclaim ethanol and the clear paste of simmer down to relative density 1.20-1.30, add ethanol to alcohol content 80-85%, cold preservation, get supernatant, add the active carbon being about inventory 1%, stir 30min, leave standstill, filter, filtrate recycling ethanol is extremely without alcohol taste, add water to amount of preparation, stir evenly, heated and boiled 40-50min, cold preservation, filter, filtrate is concentrated into 1/3 of amount of preparation, cold preservation, filter, filtrate by NaOH solution adjust ph to 6.5-7.5, heated and boiled 40-50min, add the active carbon being about amount of liquid medicine 0.5%, stir evenly, fluid temperature is down to 50-60 DEG C, leave standstill, filter, filtrate is after ultrafiltration, add the active carbon being about amount of liquid medicine 0.%, boil, filter, filtrate injects water to 1000ml, adjust ph is to 6.5-7.5, filter, embedding, sterilizing.
Radix Salviae Miltiorrhizae Flos Carthami composition grain: get Radix Salviae Miltiorrhizae 3 parts, 1 part, Flos Carthami, decoct with water twice, each 60min, filter, filtrate merges the clear paste of simmer down to relative density 1.20-1.30 (65 DEG C), add ethanol to alcohol content 75-80%, cold preservation, get supernatant, reclaim ethanol and the clear paste of simmer down to relative density 1.20-1.30, add the mixture (sucrose: dextrin=3:1) of suitable amount of sucrose powder and dextrin and the ethanol of appropriate 70%, mix becomes soft material, extrudes sieve (12-14 order) and makes granule, 60 DEG C of dryings, granulate.
1.2 experimental program
48 rats are divided into 6 groups (A, B, C, D, E, F) at random, often organize 8.According to rat body weight every day at set time administration (9:00am-12:00am), successive administration 14 days.Before first time administration, fasting 12 hours, freely drinks water.A group (CTL) rat rule every day feedwater feeding; B group (ASA) rat gavage every day aspirin solution; Gavage aspirin solution after C group (ASA-C1) tail vein injection every day Radix Salviae Miltiorrhizae Flos Carthami composite injection C1; Gavage aspirin solution after D group (ASA-C2) tail vein injection every day Radix Salviae Miltiorrhizae Flos Carthami composite injection C2; Gavage aspirin solution after E group (ASA-C3) tail vein injection every day Radix Salviae Miltiorrhizae Flos Carthami composite injection C3; Gavage aspirin solution after F group (ASA-K) gavage every day Radix Salviae Miltiorrhizae Flos Carthami composition grain.The dosage of aspirin and Radix Salviae Miltiorrhizae-Flos Carthami compositions every day is respectively 10.41mg/kg and 4.16ml/kg.Wherein, the crude drug dosage of Radix Salviae Miltiorrhizae Flos Carthami composite injection and granule every day is suitable.Within 15th day, put to death by all rats, get gastric tissue, half is soaked in for Histological evaluation in neutral formalin, and half-80 DEG C is preserved for pepsin activity evaluation.
1.3 mucosal lesion scorings
Observe the lesion of gastric mucosa under an optical microscope, and judge: mucosal epithelial cells with or without degeneration, necrosis, cell pyknosis; Mucosa lamina propria with or without congested, edema, cell infiltration; Submucosa is with or without hyperemia, edema, cell infiltration.Score according to lesion degree: 0 point (without obvious pathological changes), 0.5 point (slightly), 1 point (slightly), 2 points (moderate), 3 points (severe).Finally the pathological changes score of mucosal epithelium, mucosa lamina propria and Submucosa is added, obtains the mucosal lesion scoring of every animal.
1.4 stomach mucilage secretion are evaluated
Adopt periodic acid Schiff stain (PAS dyeing) method evaluation stomach mucilage secretion amount.Observe gastric epithelial PAS staining conditions under an optical microscope, calculate area and the accumulation optical density value (IOD) of positive staining with Image-ProPlusV6.0 (Forwindows), represent stomach mucilage secretion amount by positive staining area and accumulation optical density value.
1.5 pepsin activity evaluations
Accurately take tissue weight, the normal saline that volume ratio adds 9 times by weight makes the tissue homogenate of 10%, 2500 revs/min, centrifugal 10 minutes, gets 40 μ l and measure according to determination of peptic activity test kit after getting supernatant 10 times dilution.Every milligram of histone 37 DEG C of decomposition of protein per minute generate 1 μ g aminoacid and are equivalent to 1 enzyme activity unit.
1.6 statistical procedures
Experimental data represents with meansigma methods ± S.E.M.Group difference adopts nonparametric Mann-Whitney inspection.Significant difference is set as P<0.05.
2. experimental result
Mucosal lesion appraisal result display low-dosage aspirin continuous use can cause gastric mucosa to damage (P<0.05) for 14 days.The mucosal lesion that low-dosage aspirin causes comparatively is shown shallow, and be mainly mucosal epithelium damage, pathological manifestations is covering epithelium and glandular epithelium degeneration.When Radix Salviae Miltiorrhizae Flos Carthami compositions provided by the invention and low-dosage aspirin drug combination, mucosal lesion all has alleviating in various degree.In injection prepared by Radix Salviae Miltiorrhizae Flos Carthami compositions, when the proportioning of Radix Salviae Miltiorrhizae and Flos Carthami is 3:1, the protective effect of low-dosage aspirin mucosal lesion is obviously better than to two kinds of injection of other proportionings.The comparative result display of Radix Salviae Miltiorrhizae Flos Carthami composite injection and granule, the effect of the protection low-dosage aspirin mucosal lesion that injection has comparatively significantly (table 1).To sum up result display, Radix Salviae Miltiorrhizae and Flos Carthami proportioning are that the mucosal lesion that injection prepared by 3:1 causes antagonism low-dosage aspirin is the most effective.
In the mucosal lesion that low-dosage aspirin causes, significantly to decline (P<0.05) along with stomach mucilage secretion amount and pepsin activity significantly raises the phenomenon of (P<0.05).When Radix Salviae Miltiorrhizae Flos Carthami compositions provided by the invention and low-dosage aspirin drug combination, stomach mucilage secretion amount has rising in various degree, pepsin activity has decline in various degree, especially the Radix Salviae Miltiorrhizae Flos Carthami composite injection of 3:1 proportioning, to the improvement result of stomach mucilage secretion amount and pepsin activity the most obviously (table 1).
Table 1 different ratio Radix Salviae Miltiorrhizae-Flos Carthami compositions is to the protective effect (M ± SD) of low-dosage aspirin mucosal lesion
* represent has significant difference (P<0.05) compared with CTL; # represents there is significant difference (P<0.05) compared with ASA.
The different scheme of combination drug therapy of embodiment 2 is to the Protection of low-dosage aspirin mucosal lesion
Radix Salviae Miltiorrhizae Flos Carthami proportioning is that injection (hereinafter referred to as Radix Salviae Miltiorrhizae-Flos Carthami composite injection) prepared by 3:1 carries out administration from low-dosage aspirin according to different scheme of combination drug therapy, and concrete experimental technique is see embodiment 1.Experimental result shows, and under multiple scheme of combination drug therapy, Radix Salviae Miltiorrhizae-Flos Carthami composite injection all significantly can alleviate the mucosal lesion (table 2) that low-dosage aspirin causes.
The different scheme of combination drug therapy of table 2 is to the protective effect (M ± SD) of low-dosage aspirin mucosal lesion
Above experimental result shows, Radix Salviae Miltiorrhizae Flos Carthami composite injection provided by the invention obviously can alleviate the mucosal lesion that low-dosage aspirin causes, when treating cardiovascular and cerebrovascular disease with low-dosage aspirin drug combination, antithrombotic clinical efficacy can not only be worked in coordination with, significantly can also reduce the adjoint gastrointestinal side effect of low-dosage aspirin, for clinical prevention mucosal lesion, there is important application prospect.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, under the prerequisite not departing from the principle of the invention and design; can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (6)
1. have a compositions for the protective effects on gastric mucosa, it is characterized in that, it is made up of the raw material of following parts by weight: Radix Salviae Miltiorrhizae 1 ~ 10 part, 2 ~ 6 parts, Flos Carthami.
2. the compositions with the protective effects on gastric mucosa according to claim 1, is characterized in that, it is made up of the raw material of following parts by weight: Radix Salviae Miltiorrhizae 8 ~ 10 parts, 2 ~ 4 parts, Flos Carthami.
3. the compositions with the protective effects on gastric mucosa according to claim 1, is characterized in that, it is made up of the raw material of following parts by weight: Radix Salviae Miltiorrhizae 3 parts, 1 part, Flos Carthami.
4. have the medicine of the protective effects on gastric mucosa, it is characterized in that, it is the oral formulations or ejection preparation be made up of the extract of Radix Salviae Miltiorrhizae 3 parts of Flos Carthami 1 part and pharmaceutically acceptable carrier.
5. the application of the compositions with the protective effects on gastric mucosa described in claims 1 to 3 in preparation control mucosal lesion medicine.
6. the application in the mucosal lesion that causes at control aspirin of the medicine with the protective effects on gastric mucosa according to claim 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510860124.1A CN105250376A (en) | 2015-11-30 | 2015-11-30 | Composition having gastric mucosa protecting effect and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510860124.1A CN105250376A (en) | 2015-11-30 | 2015-11-30 | Composition having gastric mucosa protecting effect and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105250376A true CN105250376A (en) | 2016-01-20 |
Family
ID=55090512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510860124.1A Pending CN105250376A (en) | 2015-11-30 | 2015-11-30 | Composition having gastric mucosa protecting effect and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105250376A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105920096A (en) * | 2016-06-12 | 2016-09-07 | 南京中医药大学 | Composition with salviae miltiorrhiza and safflower as well as preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1679831A (en) * | 2005-01-25 | 2005-10-12 | 咸阳步长医药科技发展有限公司 | Oral medicine for cardio-cerebral blood vessel diseases and its making method |
| CN1704113A (en) * | 2004-02-20 | 2005-12-07 | 于文勇 | Chinese traditional medicinal preparation containing red sange root and safflower for treating cardiovascular and cerebrovascular diseases and preparing process thereof |
-
2015
- 2015-11-30 CN CN201510860124.1A patent/CN105250376A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1704113A (en) * | 2004-02-20 | 2005-12-07 | 于文勇 | Chinese traditional medicinal preparation containing red sange root and safflower for treating cardiovascular and cerebrovascular diseases and preparing process thereof |
| CN1679831A (en) * | 2005-01-25 | 2005-10-12 | 咸阳步长医药科技发展有限公司 | Oral medicine for cardio-cerebral blood vessel diseases and its making method |
Non-Patent Citations (1)
| Title |
|---|
| 马文胜等: "丹红注射液治疗慢性萎缩性胃炎 56 例临床疗效观察", 《吉林医学》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105920096A (en) * | 2016-06-12 | 2016-09-07 | 南京中医药大学 | Composition with salviae miltiorrhiza and safflower as well as preparation method and application thereof |
| CN105920096B (en) * | 2016-06-12 | 2020-05-08 | 南京中医药大学 | Composition of red sage root and safflower, preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101279078A (en) | Chinese medicinal composition for treating gastropathy and method of preparing the same | |
| CN102008612B (en) | Medicament for treating empyrosis and preparation method thereof | |
| CN103690582B (en) | A kind of compositions and application thereof containing dendrobium polysaccharide and atractylis concrete | |
| CN105250376A (en) | Composition having gastric mucosa protecting effect and application thereof | |
| CN105456550A (en) | Compound for preventing and treating gastric mucosal damage as well as preparation method and application of compound | |
| CN103191167B (en) | Application of eupatorium Chinese | |
| CN102716414A (en) | Anti-tumor medicinal composition containing algal polysaccharide sulfate and preparation method for composition | |
| CN104667188A (en) | Traditional Chinese medicine preparation for treating sphagitis | |
| CN103845535A (en) | Pharmaceutical composition for debriding and eliminating inflammation | |
| CN102648929A (en) | Chinese medicinal composition for treating osteoarthritis and preparation method thereof | |
| CN109939200B (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating acute kidney injury | |
| CN101129559A (en) | Lianqin liquor for treating beriberi | |
| CN112641889A (en) | Application of intestine-regulating decoction in preparation of medicament for treating Crohn's disease | |
| CN1679778A (en) | Chinese medicinal preparation for dilating coronary artery and preventing from platelet aggregation | |
| CN110420320A (en) | A kind of Chinese medicine composition for removing gout pathogenesis basis | |
| CN103446387A (en) | Traditional Chinese medicine composition for treating hyperthyroidism and preparation method thereof | |
| KR20120113186A (en) | Composition comprising oriental herbal extract for preventing or treating gastrointestinal disorder | |
| CN108236623B (en) | Pharmaceutical composition, traditional Chinese medicine oral liquid, traditional Chinese medicine granules and preparation method and application thereof | |
| CN105412226A (en) | Application of salviae miltiorrhizae and flos carthami composition to enhancement of antithrombotic function of aspirin | |
| CN106265824B (en) | Application of Fujian tea extract in preparing medicine for treating hyperlipemia | |
| CN105457019A (en) | Traditional Chinese medicine for treating infantile indigestion | |
| CN1985878B (en) | Medicine composition for treating peptic ulcer and its preparing method | |
| CN103750303A (en) | Health-care product for relieving gastralgia | |
| CN103007086A (en) | Medicament for treating ulcers and preparation method thereof | |
| CN110179876A (en) | Prevent and treat composition and preparation method that haze causes respiratory tract infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160120 |
|
| RJ01 | Rejection of invention patent application after publication |